Regulus Therapeutics (NASDAQ:RGLS) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research report released on Monday morning, Benzinga reports. HC Wainwright currently has a $9.00 target price on the biopharmaceutical company’s stock.

RGLS has been the subject of a number of other reports. Leerink Partnrs reiterated an outperform rating on shares of Regulus Therapeutics in a report on Monday, March 18th. StockNews.com assumed coverage on Regulus Therapeutics in a research note on Tuesday, April 16th. They issued a sell rating on the stock. SVB Leerink initiated coverage on Regulus Therapeutics in a research report on Monday, March 18th. They set an outperform rating and a $6.00 target price for the company. Wells Fargo & Company lifted their price target on shares of Regulus Therapeutics from $2.00 to $3.00 and gave the company an equal weight rating in a research report on Wednesday, March 13th. Finally, Canaccord Genuity Group decreased their price objective on shares of Regulus Therapeutics from $12.00 to $11.00 and set a buy rating for the company in a report on Tuesday, March 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. According to MarketBeat, Regulus Therapeutics currently has an average rating of Moderate Buy and a consensus target price of $7.25.

Regulus Therapeutics Stock Down 8.3 %

Shares of RGLS stock opened at $2.43 on Monday. The stock’s 50-day moving average is $2.32 and its two-hundred day moving average is $1.69. Regulus Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.40). On average, research analysts forecast that Regulus Therapeutics will post -0.52 EPS for the current year.

Hedge Funds Weigh In On Regulus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Victory Capital Management Inc. grew its position in Regulus Therapeutics by 5.3% in the 3rd quarter. Victory Capital Management Inc. now owns 233,207 shares of the biopharmaceutical company’s stock worth $322,000 after purchasing an additional 11,701 shares during the last quarter. FMR LLC raised its position in shares of Regulus Therapeutics by 32.4% during the third quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock valued at $4,033,000 after buying an additional 716,000 shares during the last quarter. Finally, Vivo Capital LLC bought a new stake in shares of Regulus Therapeutics in the first quarter valued at about $14,400,000. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.